FDA Panel Splits On Banning Abbott's Meridia

Law360, New York (September 15, 2010, 7:00 PM EDT) -- A U.S. Food and Drug Administration advisory panel issued a split decision Wednesday on whether Abbott Laboratories' diet pill Meridia should remain on the market, with half the panel members voting to ban it and the other half recommending new warning labels.

Abbott said in a statement Wednesday that it would now consult with the FDA about the fate of the drug, which has been linked to an increased risk of heart problems and strokes.

Rulings by the Endocrinologic and Metabolic Drugs Advisory Committee, which is...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.